The Filing Desk

Kyntra Bio vs Ovid Therapeutics

Kyntra Bio KYNB · Ovid Therapeutics OVID · Pharmaceuticals

Ovid Therapeutics reported revenue of $7 million in fiscal 2025, about the same as Kyntra Bio's $6 million in fiscal 2025. Kyntra Bio's revenue fell 78.3% in its latest year, and Ovid Therapeutics' grew 1181.3%. Kyntra Bio had an operating margin of -712.7%, against -585.2% at Ovid Therapeutics. Free cash flow was −$5 million at Kyntra Bio and −$38 million at Ovid Therapeutics.

Side by side

Kyntra BioOvid Therapeutics
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$6M$7M
Revenue growth−78.3%1,181.3%
Revenue growth a year, last 5 years−48.5%−10.3%
Gross margin91.4%—
Operating margin−712.7%−585.2%
Net margin2,848.6%−240.1%
Free cash flow−$5M−$38M
Free cash flow margin−74.7%−528.6%
Return on capital——
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count1.0%—
Last close$1.83$2.34
P/E at the last close——
Insider trades, last 12 monthsbought $19,852, sold $0sold $29,285
Piotroski F-score——
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Kyntra BioOvid Therapeutics
Operating margin
Percent of revenue
Kyntra BioOvid Therapeutics
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Kyntra BioOvid Therapeutics

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Kyntra Bio and Ovid Therapeutics pages.